Cooksey Review

Cooksey Review

The Cooksey Review was a 2006 independent assessment led by Sir David Cooksey into public sector research and development funding for health and healthcare delivery in the United Kingdom aimed at improving translation of biomedical science into patient benefit. Commissioned by the Department of Health and conducted alongside stakeholders such as the Medical Research Council, Wellcome Trust, and the National Health Service, the review shaped debates in policy arenas including the HM Treasury, Number 10 Downing Street, and Parliament. Its recommendations intersected with bodies like the National Institute for Health and Care Excellence, National Institute for Health Research, and funding streams overseen by the Medical Research Council and private funders such as the Wellcome Trust and Cancer Research UK.

Background and context

The review arose amid debates following reports from the Cooksey Review's timeframe about translational gaps highlighted by stakeholders including the Academy of Medical Sciences, Nuffield Trust, Health Select Committee (House of Commons), and researchers at institutions such as University of Oxford, Imperial College London, University College London, University of Cambridge, and the London School of Hygiene & Tropical Medicine. International comparisons referenced models like the National Institutes of Health, Veterans Health Administration, and initiatives in US HHS and the European Commission. The remit engaged commissioners from DHSS-era structures and healthcare delivery partners such as NHS Trusts, research-intensive hospitals like Guy's and St Thomas' NHS Foundation Trust and academic centres including Wellcome Trust Sanger Institute.

Key findings and recommendations

Cooksey concluded that the Medical Research Council and charities such as the Wellcome Trust were strong in basic biomedical science but that the UK lacked coherent funding for translational and late-stage clinical research, prompting recommendations to create a coherent funding architecture. He proposed establishing a health research funding stream under a new or expanded National Institute for Health Research to interface with the NHS, Clinical Research Networks, regulatory bodies like the Medicines and Healthcare products Regulatory Agency, and funders including European Research Council and UK Research and Innovation. The review recommended ring-fenced funding mechanisms within HM Treasury settlement processes and urged strengthening links with industry partners such as GlaxoSmithKline, AstraZeneca, and biotechnology clusters in the Golden Triangle. It urged enhanced support for translational platforms, clinical trials infrastructure, and workforce development tied to institutions like Charité – Universitätsmedizin Berlin as comparative models and advocated closer alignment with priority-setting bodies such as the National Institute for Health and Care Excellence.

Implementation and impact

Many recommendations fed into the formal establishment and expansion of the National Institute for Health Research and influenced funding allocations from the Department of Health and HM Treasury during subsequent Spending Reviews overseen by ministers in Whitehall. Implementation involved coordination among funders such as the Medical Research Council, Wellcome Trust, and charities like British Heart Foundation and Cancer Research UK, and engagement with industry partners like Pfizer and Novartis. The review accelerated development of Clinical Research Networks, strengthened translational hubs at centres such as Oxford Biomedical Research Centre and UCLPartners, and influenced research governance via the Health Research Authority and data linkage initiatives with NHS Digital. The impact was visible in increased funding lines for applied research, changes to grant portfolios at the Medical Research Council, and creation of career pathways for clinician-scientists associated with bodies like the Royal College of Physicians and Royal College of Surgeons.

Responses and criticism

Responses spanned praise from bodies like the Wellcome Trust and Academy of Medical Sciences for addressing the translational gap, alongside critique from think tanks such as the Nuffield Trust and commentators in outlets referencing The Lancet, BMJ, and parliamentary debates in the House of Commons. Critics argued that the review underestimated challenges in research culture at institutions like NHS Trusts and overestimated capacity of industry partnerships exemplified by deals with GlaxoSmithKline and AstraZeneca. Concerns were raised about potential crowding out of basic science funded by the Medical Research Council and charities such as Wellcome Trust, and about accountability to bodies like Public Accounts Committee (House of Commons). Others highlighted regional disparities affecting research-active centres in areas outside the Golden Triangle including Manchester, Newcastle, and Cardiff.

Legacy and influence on UK health research policy

The review left a lasting legacy by helping catalyse the National Institute for Health Research's remit, reshaping grant portfolios across the Medical Research Council, Wellcome Trust, and charity funders including Cancer Research UK and British Heart Foundation, and influencing successive government strategies produced by the Department of Health and Social Care. Its influence extended to the structuring of translational infrastructure in partnerships with industry actors like GlaxoSmithKline and AstraZeneca, and the embedding of clinical research within the NHS via networks that interfaced with regulatory agencies including the Medicines and Healthcare products Regulatory Agency and ethical oversight by bodies such as Health Research Authority. The Cooksey-led proposals informed later initiatives in research governance, funding allocation during Spending Reviews, and comparative policy learning with institutions like the National Institutes of Health and the European Commission research programmes, shaping the trajectory of UK health research into the 2010s and beyond.

Category:Health policy in the United Kingdom